水肿与退缩模式在预测管腔型乳腺癌新辅助化疗反应及生存结局中的作用
本研究纳入2017至2022年接受新辅助化疗的258例管腔型乳腺癌患者,评估传统MRI特征(BI-RADS描述符、肿瘤大小、ADC值)与新兴MRI特征(水肿与退缩模式)在化疗前、早期及化疗后的变化。结果显示弥漫性水肿及早期化疗中水肿稳定或增加是不良预测因素,而肿瘤缩小及ADC值升高为有利预测因素;将水肿与退缩模式纳入传统MRI特征后,治疗反应预测AUC从0.76-0.78提升至0.80-0.83,DFS预测C-index从0.67-69提升至0.75-0.80。
要点
- 弥漫性水肿及早期NAC中水肿稳定或增加是不良治疗反应的预测因素。
- 化疗后非同心性退缩模式及胸前或皮下水肿是无病生存期的危险因素。
- 将水肿与退缩模式加入传统MRI特征可提升治疗反应及DFS的预测性能。
核心结论
- 水肿是治疗反应和生存结局的不利预测因素,而退缩模式对预后价值贡献更大,两者可为管腔型乳腺癌的临床结局提供补充获益。
研究设计与样本
- 研究纳入2017至2022年接受新辅助化疗的管腔型乳腺癌患者258例,评估化疗前、早期及化疗后的传统MRI特征(BI-RADS描述符、肿瘤大小、ADC值)与新兴MRI特征(水肿与退缩模式)及其变化,采用单因素和多因素分析评估特征价值。
关键影像表现/征象
- 弥漫性水肿、早期NAC中水肿稳定或增加为治疗反应的不良预测因素(P<0.05)。
- 肿瘤大小缩小程度更大及ADC值升高幅度更大为治疗反应的有利预测因素(P<0.05)。
- 弥漫性水肿、胸前或皮下水肿及化疗后非同心性退缩模式为无病生存期的危险因素。
- ADC值升高幅度更大为无病生存期的保护因素。
诊断标准与关键数值
- 将水肿与退缩模式纳入传统MRI特征后,治疗反应预测AUC从0.76-0.78提升至0.80-0.83。
- 将水肿与退缩模式纳入传统MRI特征后,DFS预测C-index从0.67-69提升至0.75-0.80。
- 258例患者中77例对NAC有反应;60例随访患者中20例出现复发。
临床应用与阅片要点
- 阅片时可关注化疗前及早期化疗中水肿的范围及变化,弥漫性水肿或水肿稳定/增加提示治疗反应不佳。
- 化疗后评估退缩模式,非同心性退缩及胸前或皮下水肿提示DFS风险较高。
- 将水肿与退缩模式结合传统MRI特征(BI-RADS描述符、肿瘤大小、ADC值)可提升预测性能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIMS: To explore the independent and additional value of oedema and shrinkage patterns for predicting the disease-free survival (DFS) and neoadjuvant chemotherapy (NAC) response in luminal breast cancer (BC).
MATERIALS AND METHODS: Patients with luminal BC who underwent NAC were enrolled in this study from 2017 to 2022. Traditional MRI features include BI-RADS-based MRI descriptors, tumor size, and ADC values, while emerging MRI features include oedema and shrinkage patterns, all of which were evaluated before, early, and after NAC. The changes in features during NAC were also evaluated. The value of features was evaluated through univariate, multivariate analyses.
RESULTS: A total of 258 patients were enrolled in this study, of which 77 responded to NAC. Diffuse oedema, stable or increased oedema during early NAC were adverse predictors for treatment response, while a greater reduction in tumor size and increase in ADC value were favorable predictors (all P<0.05). Furthermore, 20 of 60 patients who were followed up experienced recurrence. Diffuse oedema, pre-pectoral or subcutaneous oedema, and non-concentric shrinkage patterns after NAC were risk factors for DFS, whereas a greater increase in ADC value was a protective factor. Incorporating oedema and shrinkage patterns into traditional MRI features improved the predictive performance for treatment response (AUC from 0.76-0.78 to 0.80-0.83) and DFS (C-index from 0.67-69 to 0.75-0.80).
CONCLUSIONS: Oedema is an unfavorable predictor for treatment response and survival outcomes, while shrinkage patterns contribute more to the prognostic value, both of which could offer supplementary benefits for clinical outcomes in luminal BC.
引用
- Sun S, Zhou J, Bai Y, et al. Role of oedema and shrinkage patterns for prediction of response to neoadjuvant chemotherapy and survival outcomes in luminal breast cancer. Clin Radiol. 2024. PMID: 38830784. doi:10.1016/j.crad.2024.04.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。